本帖最后由 老马 于 2013-3-13 13:43 编辑
+ n. A( ~! ^- T, W6 ^- A! F. \" g: ^+ z2 @" ~1 A
健择（吉西他滨）+顺铂+阿瓦斯汀/ b2 V u8 A7 q/ J. [# L
Gemzar +Cisplatin + Avastin3 T/ [% n3 ^; l. s( p: Q' I( Z
http://annonc.oxfordjournals.org/content/21/9/1804.full2 b: Z( o2 E2 _. |, P0 @( O4 F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) e4 E* y, k5 V, b/ x3 H# O) f$ A$ s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' [( l! a" |8 k6 [& _0 L! wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
C* r7 @, j/ [; Q
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 941)
3 e1 I, h0 z/ m/ N9 a) b9 x华为网盘附件：$ S" }; O% p$ K0 k' R8 U
【华为网盘】ava.JPG4 z1 Q7 }5 L" a) }$ i7 k
|
显身卡
